Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent

Fineline Cube Mar 22, 2023

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...

Company Drug

Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study

Fineline Cube Mar 22, 2023

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Company Drug

Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials

Fineline Cube Mar 22, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube Mar 22, 2023

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Deals

Smith & Nephew Partners with MedMotion for Digital Health Innovation

Fineline Cube Mar 22, 2023

UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...

Company Deals

Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services

Fineline Cube Mar 22, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...

Company

3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials

Fineline Cube Mar 22, 2023

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...

Company Deals

Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000

Fineline Cube Mar 22, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...

Company Drug

Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study

Fineline Cube Mar 22, 2023

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...

Company Deals

Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms

Fineline Cube Mar 22, 2023

Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...

Company

BeiGene Marks Topping Off of New Biologics Facility in New Jersey

Fineline Cube Mar 22, 2023

China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...

Company Deals Digital

Roche Partners with China Resource Medicine to Promote Xofluza in China

Fineline Cube Mar 22, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...

Company Deals

Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination

Fineline Cube Mar 22, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...

Company Drug

Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis

Fineline Cube Mar 21, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...

Company Deals

BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392

Fineline Cube Mar 21, 2023

Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...

Company Deals

Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology

Fineline Cube Mar 21, 2023

Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...

Company Deals

L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development

Fineline Cube Mar 21, 2023

Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...

Company Deals

T&L Biotechnology Secures RMB 100 Million in Series A Financing

Fineline Cube Mar 21, 2023

Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...

Company Drug

Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 21, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment

Fineline Cube Mar 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...

Posts pagination

1 … 601 602 603 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.